Changes in proteome solubility indicate widespread proteostatic disruption in mouse models of neurodegenerative disease
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
The deposition of pathologic misfolded proteins in neurodegenerative disorders such as Alzheimer’s disease, Parkinson’s disease, frontotemporal dementia and amyotrophic lateral sclerosis is hypothesized to burden protein homeostatic (proteostatic) machinery, potentially leading to insufficient capacity to maintain the proteome. This hypothesis has been supported by previous work in our laboratory, as evidenced by the perturbation of cytosolic protein solubility in response to amyloid plaques in a mouse model of Alzheimer’s amyloidosis. In the current study, we demonstrate changes in proteome solubility are a common pathology to mouse models of neurodegenerative disease. Pathological accumulations of misfolded tau, α-synuclein and mutant superoxide dismutase 1 in CNS tissues of transgenic mice were associated with changes in the solubility of hundreds of CNS proteins in each model. We observed that changes in proteome solubility were progressive and, using the rTg4510 model of inducible tau pathology, demonstrated that these changes were dependent upon sustained expression of the primary pathologic protein. In all of the models examined, changes in proteome solubility were robust, easily detected, and provided a sensitive indicator of proteostatic disruption. Interestingly, a subset of the proteins that display a shift towards insolubility were common between these different models, suggesting that a specific subset of the proteome is vulnerable to proteostatic disruption. Overall, our data suggest that neurodegenerative proteinopathies modeled in mice impose a burden on the proteostatic network that diminishes the ability of neural cells to prevent aberrant conformational changes that alter the solubility of hundreds of abundant cellular proteins.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP
Lewis, J., Dickson, D. W., Lin, W.-L., Chisholm, L., Corral, A., Jones, G., Yen, S.-H., Sahara, N., Skipper, L., Yager, D., et al. (2001) · Science · doi:10.1126/science.1058189 · Cited by 1,611 · cited 1×
“We also examined changes in proteome solubility in the JNPL3 model (human tau-P301L) of spinal tau pathology [58], the M83 model (human αSynA53T) of spinal αSyn pathology [31], and the G93A model (human SOD1-G93A) of spinal SOD1 pathology [37].”
Self-citationUnfolding the role of protein misfolding in neurodegenerative diseases
Soto, C. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1007 · Cited by 1,506 · cited 1×
“Neurodegenerative disorders, including Alzheimer’s disease (AD), frontotemporal dementia (FTD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS) are characterized pathologically by the accumulation of misfolded proteins (often referred to as “proteinopathies”) [9, 21, 22, 41, 85, 86].”
The Biology of Proteostasis in Aging and Disease
Labbadia, J., & Morimoto, R. I. (2015) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060614-033955 · Cited by 1,472 · cited 1×
“Considerable evidence supports the idea that the accumulation of misfolded proteins could be deleterious to the proteostasis network [5, 8, 15, 24, 44, 56, 62, 68, 73, 90, 95].”
Lewis, J., McGowan, E., Rockwood, J., Melrose, H., Nacharaju, P., Van Slegtenhorst, M., Gwinn-Hardy, K., Murphy, M. P., Baker, M., Yu, X., et al. (2000) · Nature Genetics · doi:10.1038/78078 · Cited by 1,371 · cited 2×
“The JNPL3 mouse model of tauopathy (maintained on the Swiss Webster background from Taconic) expresses mutant human tau (P301L, 4R0N) under the mouse prion promoter and develops robust tau pathology in the spinal cord and brain stem with other regions being modestly affected [59].”
Self-citationNeuronal α-Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human α-Synuclein
Giasson, B. I., Duda, J. E., Quinn, S. M., Zhang, B., Trojanowski, J. Q., & Lee, V. M.-Y. (2002) · Neuron · doi:10.1016/s0896-6273(02)00682-7 · Cited by 1,266
Self-citationPropagation of Tau Misfolding from the Outside to the Inside of a Cell
Frost, B., Jacks, R. L., & Diamond, M. I. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808759200 · Cited by 1,252 · cited 1×
“To obtain additional evidence that what was observed in our proteomics analysis of transgenic mouse tissues from tau mice was not due to the binding of cellular proteins to pathologic tau aggregates, we utilized an established paradigm of exposing mouse Neuro2a (N2a) cells to human tau aggregates [30, 36].”
Hoover, B. R., Reed, M. N., Su, J., Penrod, R. D., Kotilinek, L. A., Grant, M. K., Pitstick, R., Carlson, G. A., Lanier, L. M., Yuan, L.-L., et al. (2010) · Neuron · doi:10.1016/j.neuron.2010.11.030 · Cited by 1,118
Kawarabayashi, T., Younkin, L. H., Saido, T. C., Shoji, M., Ashe, K. H., & Younkin, S. G. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-02-00372.2001 · Cited by 1,053 · cited 1×
“, SDS) is a wellknown criterion used to distinguish natively folded proteins from those that are misfolded and/or aggregated [32, 54, 64, 80, 91, 93].”
SAINT: probabilistic scoring of affinity purification–mass spectrometry data
Choi, H., Larsen, B., Lin, Z.-Y., Breitkreutz, A., Mellacheruvu, D., Fermin, D., Qin, Z. S., Tyers, M., Gingras, A.-C., & Nesvizhskii, A. I. (2011) · Nature Methods · doi:10.1038/nmeth.1541 · Cited by 800
Office of Rare Diseases Neuropathologic Criteria for Corticobasal Degeneration
Dickson, D. W., Bergeron, C., Chin, S. S., Duyckaerts, C., Horoupian, D., Ikeda, K., Jellinger, K., Lantos, P. L., Lippa, C. F., Mirra, S. S., et al. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.11.935 · Cited by 724
CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation
Petrucelli, L. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh083 · Cited by 723
Ramsden, M., Kotilinek, L., Forster, C., Paulson, J., McGowan, E., SantaCruz, K., Guimaraes, A., Yue, M., Lewis, J., Carlson, G., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3279-05.2005 · Cited by 702 · cited 5×
“The rTg4510 model of tau pathology (maintained on a hybrid 129S6/FVB background) consists of bigenic mice that contain both human tau (P301L, 4R0N) behind by a minimal promoter disrupted by tetracycline responsive elements, and the tet-transactivator (tTA) driven by a Ca2+ calmodulin kinase II promoter (forebrain-spec…”
MethodInfluentialSelf-citationProgressive disruption of cellular protein folding in models of polyglutamine diseases
Gidalevitz, T., Ben-Zvi, A., Ho, K. H., Brignull, H. R., & Morimoto, R. I. (2006) · Science · doi:10.1126/science.1124514 · Cited by 643 · cited 1×
“elegans where muscle cells expressing aggregating mutants of huntingtin, or SOD1, failed to correctly fold co-expressed temperature-sensitive metastable proteins [33, 34].”
Seeding of Normal Tau by Pathological Tau Conformers Drives Pathogenesis of Alzheimer-like Tangles
Guo, J. L., & Lee, V. M.-Y. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.209296 · Cited by 636 · cited 6×
“gates of a synthetic tau fragment (K18) [36] (see Online Resource 1, supplemental methods).”
InfluentialAging as an event of proteostasis collapse
Taylor, R. C., & Dillin, A. (2011) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a004440 · Cited by 538 · cited 1×
“Considerable evidence supports the idea that the accumulation of misfolded proteins could be deleterious to the proteostasis network [5, 8, 15, 24, 44, 56, 62, 68, 73, 90, 95].”
Proteasome inhibition by paired helical filament‐tau in brains of patients with Alzheimer's disease
Keck, S., Nitsch, R., Grune, T., & Ullrich, O. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01642.x · Cited by 483
Proteomic and functional analyses reveal a mitochondrial dysfunction in P301L tau transgenic mice
David, D. C., Hauptmann, S., Scherping, I., Schuessel, K., Keil, U., Rizzu, P., Ravid, R., Dröse, S., Brandt, U., Müller, W. E., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500356200 · Cited by 447 · cited 1×
“One study of mice expressing tau-P30L transgenes, similar to our JNPL3 mice, identified proteins with shifts in solubility [17], and our study identified 10 of the 28 proteins previously characterized as altered (Online Resource 1, Table S13).”
Myeku, N., Clelland, C. L., Emrani, S., Kukushkin, N. V., Yu, W. H., Goldberg, A. L., & Duff, K. E. (2016) · Nature Medicine · doi:10.1038/nm.4011 · Cited by 446
TDP-43 stage, mixed pathologies, and clinical Alzheimer’s-type dementia
James, B. D., Wilson, R. S., Boyle, P. A., Trojanowski, J. Q., Bennett, D. A., & Schneider, J. A. (2016) · Brain · doi:10.1093/brain/aww224 · Cited by 407
U1 small nuclear ribonucleoprotein complex and RNA splicing alterations in Alzheimer’s disease
Bai, B., Hales, C. M., Chen, P.-C., Gozal, Y., Dammer, E. B., Fritz, J. J., Wang, X., Xia, Q., Duong, D. M., Street, C., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1310249110 · Cited by 335 · cited 1×
“Several studies have identified proteins in tissues from AD and tauopathy patients that were insoluble in detergents or otherwise exhibited altered solubility [1, 3, 35, 38, 81, 98] (Online Resource 1, Table S13), and our study identified many of the same proteins (n = 60; Fig.”
Crippa, V., Sau, D., Rusmini, P., Boncoraglio, A., Onesto, E., Bolzoni, E., Galbiati, M., Fontana, E., Marino, M., Carra, S., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq257 · Cited by 330 · cited 1×
“1 3 proteostatic activity have been reported in the presence of α-synuclein (αSyn) pathology [16, 26, 28, 104], and in tissues from mouse models that over-express ALS-associated variants of superoxide dismutase 1 (SOD1) [6, 10, 14, 50, 51, 79].”
Proteasomal degradation of tau protein
David, D. C., Layfield, R., Serpell, L., Narain, Y., Goedert, M., & Spillantini, M. G. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01137.x · Cited by 327 · cited 2×
“As previously mentioned, proteasomal impairment has been linked to tauopathy in a wide range of settings [18, 40, 55, 57, 69, 89].”
Hsp90-Tau complex reveals molecular basis for specificity in chaperone action
Karagöz, G. E., Duarte, A. M. S., Akoury, E., Ippel, H., Biernat, J., Morán Luengo, T., Radli, M., Didenko, T., Nordhues, B. A., Veprintsev, D. B., et al. (2014) · Cell · doi:10.1016/j.cell.2014.01.037 · Cited by 318
Sequestosome 1/p62 shuttles polyubiquitinated tau for proteasomal degradation
Babu, J. R., Geetha, T., & Wooten, M. W. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03181.x · Cited by 315
Hamano, T., Gendron, T. F., Causevic, E., Yen, S., Lin, W., Isidoro, C., DeTure, M., & Ko, L. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06084.x · Cited by 283
Proteostasis and the Aging Proteome in Health and Disease
Morimoto, R. I., & Cuervo, A. M. (2014) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glu049 · Cited by 277
Proteomic differences in amyloid plaques in rapidly progressive and sporadic Alzheimer’s disease
Drummond, E., Nayak, S., Faustin, A., Pires, G., Hickman, R. A., Askenazi, M., Cohen, M., Haldiman, T., Kim, C., Han, X., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1691-0 · Cited by 239
Akt and CHIP coregulate tau degradation through coordinated interactions
Dickey, C. A., Koren, J., Zhang, Y.-J., Xu, Y.-F., Jinwal, U. K., Birnbaum, M. J., Monks, B., Sun, M., Cheng, J. Q., Patterson, C., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709180105 · Cited by 226
Hales, C. M., Dammer, E. B., Deng, Q., Duong, D. M., Gearing, M., Troncoso, J. C., Thambisetty, M., Lah, J. J., Shulman, J. M., Levey, A. I., et al. (2016) · PROTEOMICS · doi:10.1002/pmic.201600057 · Cited by 99 · cited 1×
“Several studies have identified proteins in tissues from AD and tauopathy patients that were insoluble in detergents or otherwise exhibited altered solubility [1, 3, 35, 38, 81, 98] (Online Resource 1, Table S13), and our study identified many of the same proteins (n = 60; Fig.”
Wang, Y., Martinez-Vicente, M., Krüger, U., Kaushik, S., Wong, E., Mandelkow, E.-M., Cuervo, A. M., & Mandelkow, E. (2010) · Autophagy · doi:10.4161/auto.6.1.10815 · Cited by 90
Seyfried, N. T., Gozal, Y. M., Donovan, L. E., Herskowitz, J. H., Dammer, E. B., Xia, Q., Ku, L., Chang, J., Duong, D. M., Rees, H. D., et al. (2012) · Journal of Proteome Research · doi:10.1021/pr2010814 · Cited by 64 · cited 1×
“Several studies have identified proteins in tissues from AD and tauopathy patients that were insoluble in detergents or otherwise exhibited altered solubility [1, 3, 35, 38, 81, 98] (Online Resource 1, Table S13), and our study identified many of the same proteins (n = 60; Fig.”
Flach, K., Ramminger, E., Hilbrich, I., Arsalan-Werner, A., Albrecht, F., Herrmann, L., Goedert, M., Arendt, T., & Holzer, M. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.05.029 · Cited by 58 · cited 1×
“Tau also associates with other proteostatic factors, including the E3 ligases CHIP, TRAF6, and Axotrophin/MARCH7 [2, 29, 72, 83].”
Cited by
Tau drives translational selectivity by interacting with ribosomal proteins
Koren, S. A., Hamm, M. J., Meier, S. E., Weiss, B. E., Nation, G. K., Chishti, E. A., Arango, J. P., Chen, J., Zhu, H., Blalock, E. M., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-01970-9 · Cited by 122
“As expected based on our previous results [34], synthesis of many proteins was suppressed by tau expression; however, we also identified many proteins that were increased as a consequence of tau expression, which corroborates results that were recently described [41].”
ResultMyelin in Alzheimer’s disease: culprit or bystander?
Maitre, M., Jeltsch-David, H., Okechukwu, N. G., Klein, C., Patte-Mensah, C., & Mensah-Nyagan, A.-G. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01554-5 · Cited by 66
Sequence of proteome profiles in preclinical and symptomatic Alzheimer's disease
Li, X., Tsolis, K. C., Koper, M. J., Ronisz, A., Ospitalieri, S., von Arnim, C. A. F., Vandenberghe, R., Tousseyn, T., Scheuerle, A., Economou, A., et al. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12345 · Cited by 27
Dastidar, S. G., Pham, M. T., Mitchell, M. B., Yeom, S. G., Jordan, S., Chang, A., Sopher, B. L., & La Spada, A. R. (2020) · The Journal of Neuroscience · doi:10.1523/jneurosci.0940-20.2020 · Cited by 27
Metadata
- Authors
- Pace, M. C., Xu, G., Fromholt, S., Howard, J., Crosby, K., Giasson, B. I., Lewis, J., & Borchelt, D. R.
- Venue
- Acta Neuropathologica
- Published
- 2018-08-23
- Volume
- 136
- Issue
- 6
- Pages
- 919-938
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- OpenAlex
- W2888614801
- Cited by
- 31
- References
- 32
- FWCI
- 3.12
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.